RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia
- PMID: 38654089
- DOI: 10.1038/s41569-024-01034-w
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia
Comment on
-
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.JAMA Cardiol. 2024 Jul 1;9(7):620-630. doi: 10.1001/jamacardio.2024.0959. JAMA Cardiol. 2024. PMID: 38583092 Free PMC article. Clinical Trial.
-
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.N Engl J Med. 2024 May 16;390(19):1781-1792. doi: 10.1056/NEJMoa2400201. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587247 Clinical Trial.
-
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.N Engl J Med. 2024 May 16;390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587249 Clinical Trial.
References
Original articles
-
- Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2402309 (2024) - DOI - PubMed
-
- Stroes, E. S. G. et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2400201 (2024) - DOI - PubMed
-
- Gaudet, D. et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2024.0959 (2024) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
